Application of a seven-day buprenorphine transdermal patch in multimorbid patients on long-term ibuprofen or diclofenac;7-Tage-Buprenorphinpflaster bei multimorbiden Patienten mit Ibuprofen- bzw. Diclofenac-Dauertherapie: Ergebnisse einer nicht interventionellen Studie

MMW-Fortschritte der Medizin

Volumn 152, Issue , 2010, Pages 125-132

  Böhme, Klaus ^a   Heckes, Birgit ^b   Thomitzek, Karen ^b  

^a Vitos Orthopaedische Klinik   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Age; Buprenorphine; Matrix patch; Multimorbid; Musculoskeletal pain; Previous NSAID therapy

Indexed keywords

BUPRENORPHINE; DICLOFENAC; IBUPROFEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; EXERCISE; GASTROINTESTINAL TOXICITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; OBSERVATIONAL STUDY; PAIN INTENSITY; QUALITY OF LIFE; RATING SCALE; RISK FACTOR; AGED; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PAIN; PAIN ASSESSMENT; PROSPECTIVE STUDY;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUPRENORPHINE; CHRONIC DISEASE; DICLOFENAC; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; IBUPROFEN; LONG-TERM CARE; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES;

EID: 80054775835     PISSN: 14383276     EISSN: 16133560     Source Type: Journal    
DOI: 10.1007/BF03542934     Document Type: Article

References (18)

1. AGS Panel on persistent pain in older persons: The management of persistent pain in older persons. American Geriatrics Society. J. Am. Geriatr. Soc. 6 (Suppl.) (2002), S205–24.
2. Bolten, W. W., Böhme, K., Grifka, J., et al.: Low-Dose-Strong-Opioid-(LDSO)Therapie bei chronischem Arthroseschmerz. MMW Fortschr. Med. 150 (Orig.) (2008), 177–181.
3. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500054342.pdf: European Medicines Agency EMEA/CHMP/410051/2006: Opinion of the committee for medical products for human use pursant to article 5(3) of regulation (EC) No 726/2004, For nonselektive non steroidal anti-inflammatory drugs (NSAIDs).}
4. Fachinformation Norspan® Stand 03/2009.
5. Farrar, J. T., Young Jr., J. P., LaMoreaux, L., Werth, J. L, Poole, R. M.: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001), 149–158.
6. Franceschi, M., Scarcelli, C., Niro, V., et al.: Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf. 31 (2008), 545–556
7. Gosch, M., Böhmdorfer, B., Benvenuti-Falger, U., et al.: Polypharmazie und Schmerztherapie. Wien. Med. Wochenschr. 160 (2010), 286–292.
8. Heckes, B., Ritzdorf, I.: Wirksamkeit und Sicherheit eines Buprenorphin-haltigen 7-Tage-Pflasters (Norspan®) bei chronischen opioidpflichtigen Schmerzen. Schmerz 23 (Suppl. 1) (2009), 67 Abstract PO7.5.
9. James, I. G. V., O’Brien, C. M., McDonlad, C. J.: A randomized, double-blind double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (Butrans® seven-day patches) with buprenorphine sublingual tablets (Temgesic®) in patients with osteoarthritis pain. J. Pain Symp. Manage. 40 (2010), 266–278.
10. Likar, R.: Safety of pain management with transdermal buprenorphine. Ther Clin Risk Manag 2 (2006), 115–125.
11. Nolte, T.: Aktuelle Schmerztherapie: Abschied vom WHO-Stufenschema. MMW Fortschr. Med. 151 (2009), 56–60.
12. Pergolizzi, J., Böger, R. H., Budd, K., et al.: Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 8 (2008), 287–313.
13. Reidenberg, B., Eltahtawy, A., Munera, C., Cipriano, A., Tonelli, A., Reder, R.: Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. J. Clin. Pharmacol. 41 (2001), 1027.
14. Schutter, U., Ritzdorf, I., Heckes, B.: Chronische Arthroseschmerzen: Effektivität und Verträglichkeit eines 7-Tage-Pflasters mit niedrig dosiertem Buprenorphin. MMW Fortschr. Med. 150 (Orig.) (2008), 96–103.
15. Schutter, U., Ritzdorf, I., Heckes, B.: 7-Tage-Pflaster mit Buprenorphin — eine Option, wenn die Therapie mit Tramadol bzw. Tilidin/Naloxon unzureichend ist. MMW Fortschr. Med. 152 (Orig.) (2010), 62–69.
16. Sinatra, R.: Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain. JABFM 19 (2006), 165–177.
17. Sittl, R., Nuijten, M., Nautrup, B. P.: Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin. Ther. 28 (2006), 1144–1154.
18. Vadivelu, N., Hines, R. L.: Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin. Interv. Aging 3 (2008), 421–430.